161 related articles for article (PubMed ID: 16536473)
21. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
23. A Fusion Protein of RGD4C and β-Lactamase Has a Favorable Targeting Effect in Its Use in Antibody Directed Enzyme Prodrug Therapy.
Wang H; Zhou XL; Long W; Liu JJ; Fan FY
Int J Mol Sci; 2015 Apr; 16(5):9625-34. PubMed ID: 25927583
[TBL] [Abstract][Full Text] [Related]
24. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.
Willuda J; Honegger A; Waibel R; Schubiger PA; Stahel R; Zangemeister-Wittke U; Plückthun A
Cancer Res; 1999 Nov; 59(22):5758-67. PubMed ID: 10582696
[TBL] [Abstract][Full Text] [Related]
25. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
26. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
27. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
28. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM
Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557
[TBL] [Abstract][Full Text] [Related]
29. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
30. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
[TBL] [Abstract][Full Text] [Related]
31. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
32. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Singh RK; Kumar S; Prasad DN; Bhardwaj TR
Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
[TBL] [Abstract][Full Text] [Related]
34. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
[TBL] [Abstract][Full Text] [Related]
35. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
36. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy.
Harding FA; Liu AD; Stickler M; Razo OJ; Chin R; Faravashi N; Viola W; Graycar T; Yeung VP; Aehle W; Meijer D; Wong S; Rashid MH; Valdes AM; Schellenberger V
Mol Cancer Ther; 2005 Nov; 4(11):1791-800. PubMed ID: 16276001
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.
Vrudhula VM; Svensson HP; Kennedy KA; Senter PD; Wallace PM
Bioconjug Chem; 1993; 4(5):334-40. PubMed ID: 8274516
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Rodrigues ML; Carter P; Wirth C; Mullins S; Lee A; Blackburn BK
Chem Biol; 1995 Apr; 2(4):223-7. PubMed ID: 9383424
[TBL] [Abstract][Full Text] [Related]
40. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
